echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Brain: Pathological severity of AD covariation and potential genetics affect AD grouping and treatment

    Brain: Pathological severity of AD covariation and potential genetics affect AD grouping and treatment

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lewy body dementia (DLB) is a fatal neurological disease characterized by a combination of cognitive fluctuations, Parkinson's disease, visual hallucinations, and rapid eye movement behavior disorder
    .


    This type of dementia is one of the most common neurological diseases in the general population, accounting for approximately 7.


    APOE sites are closely related to the risk of Alzheimer's disease and Lewy body (DLB) dementia
    .


    In particular, the role of the apolipoprotein eε4 allele as a presumptive driving factor of α-synuclein pathology is a hotly debated topic


    Karri Kaivola et al
    .


    conducted a comprehensive evaluation of 2466 DLB patients and 2928 neurologically healthy elderly controls .


    Karri Kaivola et al


    Karri Kaivola like APOE-stratified using genome-wide association study found that the method, the relevant (p = 6.
    58 x 10 GBA DLB patients with no risk of APOE -.
    9
    = 3.
    41 for, 95% CI = 2.
    25-5.
    17), but not with patients with DLB APOE ( p = 0.
    034, = 1.
    87, 95%, 95% CI = 1.
    05-3.
    37)
    .

    - 9

    Analytical method

    Analytical method

    Demographic characteristics of DLB ​​subgroups

    Demographic characteristics of DLB ​​subgroups

    Then 495 cases were divided into three groups based on the accompanying pathological changes of AD comorbidities: pure DLB (n = 88), DLB-intermediate AD comorbidity (DLB+iAD, n = 66), and DLB-advanced AD comorbidity (DLB+ AD,n = 341)
    .

    Except for 2928 neurological healthy controls, the correlation of apolipoprotein e ε4 in each group was tested
    .

    The study found that APOEε4 is related to DLB+AD (p = 1.
    29 x10 -32 , OR=4.
    25, 95% CI = 3.
    35-5.
    39) and DLB+ iAD (p = 0.
    0011, = 2.
    31, 95% CI 3.
    83 = 1.
    40), but with pure DLB is irrelevant ( p = 0.
    31, OR=0.
    75, 95% CI 1.
    30 = 0.
    43)
    .

    APOEε4 is related to DLB+AD (p = 1.
    29 x10 -32 , OR=4.
    25, 95% CI = 3.
    35-5.
    39) and DLB+ iAD (p = 0.
    0011, = 2.
    31, 95% CI 3.
    83 = 1.
    40), but has nothing to do with pure DLB ( p = 0.
    31, OR=0.
    75, 95% CI 1.
    30 = 0.
    43)
    .


    -32 p

    This study shows that APOE ε4 is not an independent driving factor of α-synuclein pathology in DLB
    .


    On the contrary, the severity of AD covariation pathology affects the correlation of APOE ε4


    The severity of


    Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups, Brain, 2021;, awab402, https://doi.


    Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups, Brain, 2021 ;, awab402, https://doi.
    org/10.
    1093/brain/awab402 in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.